Beamion™ LUNG‑2: Phase III trial of zongertinib in HER2‑mutant advanced NSCLC (NCT06151574)

Beamion™ LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-center trial evaluating orally administered zongertinib compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD mutations (NCT06151574)^1–3

AUC, area under the curve; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; IV, intravenous; NSCLC, non-small cell lung cancer; OR, objective response; OS, overall survival; PFS, progression-free survival; PROs, patient-reported outcomes; Q3W, every 3 weeks; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumours; SOC, standard of care; TKD, tyrosine kinase domain.